NATIONAL HEALTHCARE CORP (NHC)
Sector: Health Care
2026 Annual Meeting Analysis
NATIONAL HEALTHCARE CORP · Meeting: May 7, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors: Emil E. Hassan, Lisa Piercey, M.D., and William A. Adams
Hassan has served since 2004 with full attendance, brings extensive management and financial experience, and NHC's 3-year stock return of +207.9% dramatically outpaces the IHF benchmark (iShares U.S. Healthcare Providers ETF) by +221.2 percentage points, far exceeding the 65-point threshold required to trigger a concern, so no TSR flag applies.
Piercey joined the board in November 2025, well within the 24-month new-director exemption window, so she is fully exempt from any TSR review; she brings strong healthcare operational and governance credentials as a former state health commissioner and healthcare executive.
Adams joined the board in February 2026 and is within the 24-month new-director exemption, so no TSR trigger applies; however, shareholders should note he is the nephew of Chairman Robert G. Adams and son of former board member W. Andrew Adams, creating a familial relationship with senior board leadership, though the board classifies him as independent and his long-term care and business operations background is relevant to NHC's business.
All three nominees pass the TSR screen decisively — NHC's 3-year price return of +207.9% outpaces the IHF (iShares U.S. Healthcare Providers ETF) benchmark by over 221 percentage points, well above the 65-point threshold required to trigger board accountability concerns. Piercey and W.A. Adams joined within the past 24 months and are exempt from TSR review. The familial connection of W.A. Adams to the chairman and a former director is worth noting but does not rise to a disqualifying level given his relevant industry experience.
Say on Pay
✓ FORCEO
Stephen F. Flatt
Total Comp
$2,685,370
Prior Support
96%%
CEO Stephen F. Flatt received total compensation of $2,685,370 in 2025, which is reasonable for a $2.5 billion market cap healthcare company and well within benchmark expectations for a CEO at this company size. The compensation program is substantially performance-based — the largest component is a bonus pool tied to 5% of pre-tax earnings (a clear and measurable financial result), with 80% paid in cash and 20% in restricted stock that vests over three years, meaning executives only earn large payouts when the company generates strong profits. NHC's stock returned +207.9% over three years, vastly outperforming the IHF (iShares U.S. Healthcare Providers ETF) benchmark, confirming that above-benchmark incentive pay is fully justified by shareholder outcomes. The prior year say-on-pay vote received 96% support, a clawback policy is in place, and no governance red flags are present.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche, LLP
Tenure
1 yrs
Audit Fees
$1,451,106
Non-Audit Fees
$0
Deloitte was newly appointed in April 2025, replacing Ernst & Young, so tenure is less than one year and the long-tenure concern does not apply. Non-audit fees are zero, meaning there is no independence concern from non-audit work. Deloitte is a Big Four firm fully appropriate for a $2.5 billion public company, and the audit committee conducted a thorough independence review before engagement.
Overall Assessment
NHC's 2026 annual meeting ballot is straightforward with no significant red flags across any of the three proposals. The company's outstanding stock performance — a 3-year return of +207.9% compared to a -13.3% return for the IHF (iShares U.S. Healthcare Providers ETF) benchmark — validates the pay-for-performance alignment, supports the director slate, and provides a strong backdrop for a FOR vote on all items.